Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.

Autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) is the technique of administrating a short immunosuppressive regimen over 4-6 days (depending on the drug regimen) followed by intravenous infusion of one's own hematopoietic stem cells to hasten hematopoietic recovery. The toxicity and efficacy of the procedure depend on the regimen and on patient selection and, to a lesser extent, on center experience. MS-specific nonmyeloablative regimens are less toxic and safer than myeloablative regimens that were initially developed for cancer. To date, there have been no randomized trials comparing the different regimens. HSCT like all immune-based therapy is more effective for the inflammatory phase of MS. It is effective for relapsing-remitting MS, less effective for active secondary progressive MS (SPMS), and almost ineffective for nonactive SPMS and primary progressive MS. Effectiveness and superiority of HSCT have been reported in a phase III randomized trial against the best available disease-modifying therapies at that time (mostly natalizumab) and in large meta-analyses. Compared to disease-modifying therapies, HSCT demonstrates posttransplant drug-free meaningful improvement of neurologic disability and quality of life for prolonged long-term follow-up in most patients.